Related references
Note: Only part of the references are listed.Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium
Daniele Barbaro et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Lack of Association between Urinary Iodine Excretion and Successful Thyroid Ablation in Thyroid Cancer Patients
Hernan P. Tala Jury et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Quality of Life and Effectiveness Comparisons of Thyroxine Withdrawal, Triiodothyronine Withdrawal, and Recombinant Thyroid-Stimulating Hormone Administration for Low-Dose Radioiodine Remnant Ablation of Differentiated Thyroid Carcinoma
Jandee Lee et al.
THYROID (2010)
Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer
Fabian Pitoia et al.
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2009)
Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH
Nikos Emmanouilidis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Chromosome Translocation Frequency after Radioiodine Thyroid Remnant Ablation: A Comparison between Recombinant Human Thyrotropin Stimulation and Prolonged Levothyroxine Withdrawal
Anna Frigo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
David S. Cooper et al.
THYROID (2009)
Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity
Pedro Weslley Rosario et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Expanding indications for recombinant human TSH in thyroid cancer
Bryan R. Haugen et al.
THYROID (2008)
A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer
Tania Pilli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer
Pedro W. Rosario et al.
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2007)
Positive predictive value of detectable stimulated Tg during the first year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months
Maristane M. A. Valadao et al.
THYROID (2006)
Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants
Danielle Barbaro et al.
NUCLEAR MEDICINE COMMUNICATIONS (2006)
Testicular function after radioiodine therapy in patients with thyroid cancer
Pedro W. S. Rosario et al.
THYROID (2006)
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study
F Pacini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Assessing hypothyroidism in the preparation of patients with thyroid cancer - Cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone, and absence from work
PWS Rosario et al.
ENDOCRINOLOGIST (2006)
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
Furio Pacini et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Ovarian function after radioiodine therapy in patients with thyroid cancer
PWS Rosário et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2005)
Second primary malignancies in thyroid cancer patients
C Rubino et al.
BRITISH JOURNAL OF CANCER (2003)
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation
D Barbaro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients
E Baudin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Ablation of thyroid residues with 30 mCi 131I:: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal
F Pacini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients
ID Hay et al.
WORLD JOURNAL OF SURGERY (2002)
Share Paper
